vi New Patents

tosyl ceramide, and galactosyl ceramide are syn- thesized in substantially pure stereochemical form from alkenyl, C-18 azido alcohols and pro- tected fluoroglycosides and are employed as antigens in the production of antibodies useful, for example, in the treatment of disease.

4978502

I M M U N O A S S A Y O R D I A G N O S T I C D E V I C E A N D

M E T H O D O F M A N U F A C T U R E

Charles M Dole, Gary L Webster, Ward Smith assigned to Dole Associates Inc

Liquid containers or receptacles are disclosed with cooperating means for rupturing the recep- tacles to release contained fluid to rain upon test specimens. Structure is disclosed for rupturing receptacles in response to relative motion occur- ring between receptacles and test specimen sup- port members or in response to punch means formed integrally with a receptacle. A method of molding a liquid receptacle with an integrally formed punch means for rupturing the recep- tacle is also disclosed.

4978622

C Y T O P H A G A - D E R I V E D I M M U N O P O T E N T I A T O R

A method of photodynamic therapy employing an electron trapping material as the light source. The electron trapping material is charged with light, which raises electrons in the material from a ground level to a higher trapping energy level. The material is then introduced into a patient's body, where it delivers light to and activates an antibody which has been retained in cancerous tissue. The electron trapping material can be either a deep trap or shallow trap phosphor. In the former case, stimulation of the charged material with infrared energy releases electrons from their traps, resulting in the emission of light within the patient's body. In the latter case, the material emits light immediately after charging with an intensity that decreases in inverse por- portion to time. The electron trapping material may be provided in the form of a powder which can be inhaled for treatment of lung cancer, or suspended in a liquid which can be ingested, in- jected, or circulated in cavities of the body to treat other organs.

4980162

L I V E V A C C I N E F O R C O N T A G I O U S D I S E A S E S O F

C H I C K E N S

Takash Honda, Akira Taneno, Takum Hanaki, Masanobu Eto, Kumamoto, Japan assigned to Juridical Foundation the Chemosero- Therapeutic Research Institute

Robert Mishell, William Usinger assigned to Re- gents of the University of California

Substantially pigment-free gliding bacteria ad- juvant (GBA) is isolated from medium in which Cytophaga strain GB-2 has been cultured by extraction with acetone to remove pigment, en- zymatic digestion and filtration to remove residual protein and nucleic acids, and affinity chromatography to remove residual lipopolysaccharide. This pure form of GBA shows unexpectedly high specific immuno- potentiating activity relative to crude GBA.

A live vaccine for infectious laryngotracheitis, which comprises culture cells infected with at- tenuated infectious laryngotracheitis virus. Also, a live combined vaccine for infectious laryngotracheitis and Marek's disease, which comprises culture cells infected with attenuated viruses off these two diseases. These vaccines can be used on day-old (newborn) chicken, by sub- cutaneous or intramuscular injection, to give them immunity from infection by the virus or viruses.

4980455

4979935

M E T H O D O F P H O T O D Y N A M I C T H E R A P Y E M P L O Y I N G E L E C T R O N T R A P P I N G

M A T E R I A L

N O V E L P O L Y P E P T I D E S A N D P R O D U C T I O N T H E R E O F

Masao Sakaguchi, Susumu Honda, Osamu Nishimura, Ikeda, Japan assigned to Takeda Chemical Industries Ltd

Joseph Lindmayer assigned to Quantex Cor- The present invention provides a novel poly- poration peptide which shows higher IFN- gamma ac-